Skip to main content

Table 1 Patient demographics and baseline disease characteristics

From: Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Characteristic Daratumumab 16 mg/kg (n = 32)
Age n = 32
 Median (range), years 56.0 (22–78)
 < 65 years, n (%) 24 (75.0)
 65–74 years, n (%) 7 (21.9)
 ≥ 75, n (%) 1 (3.1)
Sex, n (%) n = 32
 Male 23 (71.9)
 Female 9 (28.1)
Asian, n (%) 32 (100)
ECOG PS score, n (%) n = 32
 0 14 (43.8)
 1 15 (46.9)
 2 3 (9.4)
Median (range) time since diagnosis, months 24.0 (3.1–185.4)
Percentage of CD38 expression n = 22
 Median (range), % 45.0 (0–100)
 ≥ 0% to 49%, n (%) 11 (50.0)
 ≥ 50%, n (%) 11 (50.0)
H-score of CD38 expression n = 22
 Median (range) 67.5 (0–300)
 ≥ 0 to 49, n (%) 10 (45.5)
 ≥ 50, n (%) 12 (54.5)
Plasma EBV-DNA, kIU/L n = 31
 Median (range) 3800.0 (0–11,291,151)
β2 microglobulin, mg/L n = 31
 Median (range) 3.0 (1.7–11.5)
Site of disease involvement at initial diagnosis, n (%) n = 31
 Upper aerodigestive tract only 17 (54.8)
 Extra-upper aerodigestive tract only 5 (16.1)
 Both 9 (29.0)
PINK, n (%) n = 31
 Low 8 (25.8)
 Intermediate 15 (48.4)
 High 8 (25.8)
PINK-E, n (%) n = 30
 Low 9 (30.0)
 Intermediate 13 (43.3)
 High 8 (26.7)
Median (range) prior lines of therapy 2 (1–8)
Prior lines of therapy, n (%) n = 32
 1 11 (34.4)
 2 8 (25.0)
 ≥ 3 13 (40.6)
Prior therapies, n (%) n = 32
 L-asparaginase–containing regimen 27 (84.4)
 Radiotherapy 21 (65.6)
 Cancer-related surgery/procedure 15 (46.9)
 Anthracycline-based regimen 8 (25.0)
 Autologous stem cell transplant 4 (12.5)
  1. EBV, Epstein–Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; PINK, prognostic index of natural killer lymphoma; PINK-E, prognostic index for natural killer cell lymphoma–Epstein–Barr virus
\